GlySure Wins 2013 Small Business of the Year and New Product of the Year
GlySure recognized by BIG for unparalleled progress in delivering continuous blood glucose monitoring technology to the healthcare marketplace
OXFORD, England, October 1, 2013 /PRNewswire/ –
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM)
systems, today announced that it has won two major awards in the 2013 BIG (Business
Intelligence Group) Awards for Business.
BIG has selected GlySure as Small Business of the Year and it also won New Product of
the Year for its CBGM technology.
Business Intelligence Group’s BIG Awards specialize in recognizing top performing
companies and organizations. The organization’s proprietary and unique scoring system
selectively measures performance across multiple business domains, and rewards companies
whose achievements stand above those of their peers.
“Glysure’s mission and product to help control glucose levels in real time is clearly
in demand,” said Dawn Fordyce of the Business Intelligence Group. “With so much at stake,
Glysure’s continuous blood glucose monitoring system will surely save countless lives and
Over two years of human use trials in over 150 intensive care unit (ICU) patients have
proven that GlySure’s CBGM technology can be used to continuously measure glucose levels
with an extremely high degree of accuracy and repeatability across three-to-five days of a
patient’s stay, which is key to improving outcomes and reducing costs in the ICU. GlySure
recently commenced a multi-center CE Trial on cardiac surgery patients, which the company
expects to complete this fall.
“It is a great honor to be recognized by the Business Intelligence Group,” said
GlySure CEO Chris Jones. “This industry recognition validates the tremendous momentum
we’ve achieved to date in delivering on the promise of Tight Glycemic Control.”
GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
The company has demonstrated through ICU testing highly accurate sensors which can provide
continuous glucose readings throughout the length of a patient’s stay in the ICU. GlySure
was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30
employees. The company’s products are not approved for use in the U.S. or Europe.
Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. firstname.lastname@example.org Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. email@example.com